Events
via Zoom
Research Ethics and Policy Series (REPS) | Jason Karlawish, MD
Learn More
2021-10-04 12:00:00
2021-10-04 13:00:00
America/New_York
Research Ethics and Policy Series (REPS) | Jason Karlawish, MD
What just happened? The strange tale of the FDA’s approval of aducanumab for the treatment of Alzheimer’s disease
Jason Karlawish, MD
Professor of Medicine, Medical Ethics and Health Policy, and Neurology
Co-Director, Penn Memory Center
Director, Outreach and Recruitment Core, Research Education Component of the Penn Alzheimer’s Disease Research Center
Monday, October 4, 12:00-1:00p Eastern
Via Zoom. Register in advance:
https://upenn.zoom.us/meeting/register/tJIvdOqqpzMsEtR8ZdMLhHCPr963XXEYQEVf
The meeting link will be provided automatically upon registration.
Abstract: On the morning of June 7, 2021, the idea of using a positron emission tomography (PET) measure of beta-amyloid as a surrogate for the care of patients with Alzheimer disease was an important hypothesis in need of more research. By the evening of June 7, it was clinical practice.
This revolution in care was the aftermath of not a scientific breakthrough but the imperious decision of a divided Food and Drug Administration (FDA). The FDA had approved Biogen’s drug aducanumab for the treatment of Alzheimer disease. The agency argued that the drug’s ability to reduce beta-amyloid is an adequate surrogate for clinical benefit. Jason Karlawish will discuss why this controversial decision continues to reverberate throughout the American health care system. It has exposed enduring controversies in developing treatments for brain diseases, the steady breakdown in processes at FDA, the need to revisit why we even have an FDA, and how, in America, a disease does not fully exist until it has a business model.
For more information, please contact Mary.Pham@pennmedicine.upenn.edu.
via Zoom
Penn Medical Ethics
via Zoom
Penn Bioethics Seminar Series (PBS) | Kate Saylor, PhD
Learn More
2021-10-05 12:00:00
2021-10-05 13:00:00
America/New_York
Penn Bioethics Seminar Series (PBS) | Kate Saylor, PhD
Fairness-informed cost utility analysis of population genetic screening
Kate Saylor, PhD
Postdoctoral ELSI Fellow, Medical Ethics and Health Policy, Perelman School of Medicine
Tuesday, October 5, 2021, 12:00-1:00p Eastern
Via Zoom. Register in advance:
https://upenn.zoom.us/meeting/register/tJ0vceygqDIvE9M3VaWpXefaZkcrnN-5132J
The meeting link will be provided automatically upon registration.
Abstract: To be shared.
For more information, please contact Mary.Pham@pennmedicine.upenn.edu.
via Zoom
Penn Medical Ethics
via Zoom
Penn Bioethics Seminar Series (PBS) | Rebecca Mueller, PhD
Learn More
2021-10-12 12:00:00
2021-10-12 13:00:00
America/New_York
Penn Bioethics Seminar Series (PBS) | Rebecca Mueller, PhD
The genome and the biome: Cystic fibrosis at six feet apart
Rebecca Mueller, PhD
Postdoctoral ELSI Fellow, Medical Ethics and Health Policy, Perelman School of Medicine
Tuesday, October 12, 2021, 12:00-1:00p Eastern
Via Zoom. Register in advance:
https://upenn.zoom.us/meeting/register/tJUrde-ppzMrGt0PRkan3KUua1a1TBDdkTnX
The meeting link will be provided automatically upon registration.
Abstract: To be shared.
For more information, please contact Mary.Pham@pennmedicine.upenn.edu.
via Zoom
Penn Medical Ethics
via Zoom
Penn Bioethics Seminar Series (PBS) | Latisha Thompson, MSW, MPH
Learn More
2021-10-19 12:00:00
2021-10-19 13:00:00
America/New_York
Penn Bioethics Seminar Series (PBS) | Latisha Thompson, MSW, MPH
Do healthcare systems have a role in reducing social and economic inequities?
Latisha Thompson, MSW, MPH
Licensed Social Worker, University of Pennsylvania Health System
Tuesday, October 19, 2021, 12:00-1:00p Eastern
Via Zoom. Register in advance:
https://upenn.zoom.us/meeting/register/tJEoduypqjkvGddMTCNYzBjslSJlgJabgAPd
The meeting link will be provided automatically upon registration.
Article: https://hphr.org/30-articles-thompson/
Abstract: The link between individual social and economic needs and health outcomes is well-known and investigated in the field of public health (Braveman et al., 2011; Evans et al., 1994; Galea et al., 2011; Link & Phelan, 1995; Marmot, 2004; Marmot & Wilkinson, 2005)). As a result, screening for social needs and implementing interventions are becoming a mainstay value-based strategy among many US health systems (L. M. Gottlieb et al., 2017; Horwitz et al., 2020). However, in the year-long presence of the novel coronavirus disease (COVID-19) pandemic, recent studies have suggested that social risk factors, such as financial, housing, and food insecurity, may have worsened, leading to a burgeoning social and economic crisis in the United States (Bartsch et al., 2020; Dunn et al., 2020; Sharma et al., 2020). Especially among vulnerable populations, these consequences have had a critical impact on national rates of COVID-19 morbidity and mortality (Van Dyke et al., 2021).
Health care systems must universalize social needs screening and response programming in order to meet the complex social and health needs of patients, during and beyond this public health emergency. This editorial aims to highlight the essential role of healthcare systems in mitigating unmet social needs during and beyond the COVID-19 pandemic. Here, we will describe how the COVID-19 pandemic exacerbates existing social and economic inequities, highlight the current role of the health-care system in responding to individual and population-level health outcomes, and examine two large health-care systems’ social needs referral and response programs piloted before and during the current public health emergency. Lastly, we will conclude with possible implications and future directions for public health, and other stakeholders, in addressing these dual crises during and beyond the pandemic.
For more information, please contact Mary.Pham@pennmedicine.upenn.edu.
via Zoom
Penn Medical Ethics